title: Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40.
abstract: OBJECTIVE
  To investigate the course of subfoveal pigment epithelial detachments (PEDs) in eyes with age-related macular degeneration (AMD) and best-corrected visual acuity (BCVA) ≥20/40.
  
  
  METHODS
  Thirty-seven eyes of 35 patients with a subfoveal PED were divided into an avascular PED group (n = 11), a vascularized PED group due to polypoidal choroidal vasculopathy (PCV, n = 14) and an occult choroidal neovascularization (CNV) group (n = 12). Intravitreal bevacizumab or ranibizumab was given as needed. The BCVA, central foveal thickness, PED thickness, and lesion size were measured at baseline and at 2 years after the initial examination.
  
  
  RESULTS
  The BCVA did not change significantly in the avascular group, decreased from 0.06 ± 0.11 to 0.23 ± 0.15 logMAR units in the PCV group and from 0.12 ± 0.12 to 0.71 ± 0.70 logMAR units in the CNV group. At 2 years, the central foveal and PED thicknesses were not significantly different among the 3 groups, and the lesion was significantly larger in the PCV and CNV groups than in the avascular group.
  
  
  CONCLUSIONS
  The vascularized PED cases had a poorer visual outcome than avascular PEDs with anti-VEGF drugs at the 2-year follow-up.
authors.affiliation: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Japan. babatakayuki@nifty.com
authors.forename: Takayuki
authors.initials: T
authors.lastname: Baba
authors.forename: Masayasu
authors.initials: M
authors.lastname: Kitahashi
authors.forename: Mariko
authors.initials: M
authors.lastname: Kubota-Taniai
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Oshitari
authors.forename: Shuichi
authors.initials: S
authors.lastname: Yamamoto
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D002829:Choroid / Q000098:blood supply; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005584:Fovea Centralis; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D011127:Polyps / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D055213:Retinal Pigment Epithelium; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007208:Indocyanine Green; D000069579:Ranibizumab